243 related articles for article (PubMed ID: 34751487)
1. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population.
Yang S; Cheng J; Zhang R; Sun H; Zhang H; Lyu S; Duan W
Hepatol Res; 2022 Feb; 52(2):176-186. PubMed ID: 34751487
[TBL] [Abstract][Full Text] [Related]
2. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Hepatol Commun; 2022 Aug; 6(8):2070-2078. PubMed ID: 35470984
[TBL] [Abstract][Full Text] [Related]
3. Associations of depression score with metabolic dysfunction-associated fatty liver disease and liver fibrosis.
Cai H; Zhang R; Zhao C; Wang Y; Tu X; Duan W
J Affect Disord; 2023 Aug; 334():332-336. PubMed ID: 37142003
[TBL] [Abstract][Full Text] [Related]
4. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis.
Kim D; Dennis BB; Cholankeril G; Ahmed A
J Affect Disord; 2023 May; 329():184-191. PubMed ID: 36841305
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
7. Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA: a Nationwide Cross-Section Study.
Yu G; Liu L; Qin T; Luo Y; Song C; Chen X; Duan H; Jiang Y; Zeng H; Wan H; Shen J
Biol Trace Elem Res; 2024 Jan; 202(1):87-98. PubMed ID: 37079265
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
9. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
10. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
Cen C; Fan Z; Ding X; Tu X; Liu Y
Sci Rep; 2024 Jun; 14(1):12645. PubMed ID: 38825630
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population.
Ciardullo S; Perseghin G
Liver Int; 2021 Jun; 41(6):1290-1293. PubMed ID: 33590934
[TBL] [Abstract][Full Text] [Related]
12. The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study.
Xing M; Ni Y; Zhang Y; Zhao X; Yu X
Front Nutr; 2023; 10():1246157. PubMed ID: 38024359
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey.
Ciardullo S; Monti T; Perseghin G
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):384-390.e1. PubMed ID: 32623006
[TBL] [Abstract][Full Text] [Related]
14. Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia.
Chihota BV; Riebensahm C; Muula G; Sinkala E; Chilengi R; Mulenga L; Bosomprah S; Vinikoor MJ; Bolton-Moore C; Egger M; Rauch A; Berzigotti A; Wandeler G;
BMJ Open Gastroenterol; 2022 Jul; 9(1):. PubMed ID: 35831020
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016.
Zhang HJ; Wang YY; Chen C; Lu YL; Wang NJ
Chin Med J (Engl); 2021 Jun; 134(13):1593-1601. PubMed ID: 34091530
[TBL] [Abstract][Full Text] [Related]
16. Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease.
Huh JH; Kim KJ; Kim SU; Cha BS; Lee BW
Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):241-247. PubMed ID: 35365418
[TBL] [Abstract][Full Text] [Related]
17. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
Cheng YM; Hsieh TH; Wang CC; Kao JH
JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population.
Fan J; Luo S; Ye Y; Ju J; Zhang Z; Liu L; Yang J; Xia M
Nutr Metab (Lond); 2021 Sep; 18(1):82. PubMed ID: 34496912
[TBL] [Abstract][Full Text] [Related]
19. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
20. Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease.
Lee CH; Lui DT; Li RH; Yuen MM; Fong CH; Leung AP; Chu JC; Mak LL; Lam TH; Woo J; Woo YC; Xu A; Tse HF; Tan KC; Cheung BM; Yuen MF; Lam KS
Front Endocrinol (Lausanne); 2022; 13():1056562. PubMed ID: 36686469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
